Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective | Zendy

Richard A. Alm | Zendy; Robert E. McLaughlin | Zendy; Veronica N. Kos | Zendy; Hélio S. Sader | Zendy; Joseph P. Iaconis | Zendy; Sagar Lahiri | Zendy

Open Access

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective

Author(s) -

Richard A. Alm,

Robert E. McLaughlin,

Veronica N. Kos,

Hélio S. Sader,

Joseph P. Iaconis,

Sagar Lahiri

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku114

Subject(s) - penicillin binding proteins , cephalosporin , staphylococcus aureus , microbiology and biotechnology , penicillin , methicillin resistant staphylococcus aureus , broth microdilution , antibiotics , medicine , biology , minimum inhibitory concentration , bacteria , genetics

Ceftaroline, approved in Europe in 2012, has activity against methicillin-resistant Staphylococcus aureus (MRSA), with MIC90 values of 1-2 mg/L depending on geographical location. During a global 2010 surveillance programme, conducted prior to the European launch, 4 S. aureus isolates, out of 8037 tested, possessing ceftaroline MIC values of >2 mg/L were identified. The objective of this study was to characterize these four isolates to elucidate the mechanism of ceftaroline resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research